Pharming Group Engages with Investors This November
Leiden, the Netherlands — Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) has announced its scheduled participation in an important investor conference taking place this month. The event promises key opportunities for stakeholders to connect with the company’s leadership and gain insights into its pipeline and future direction.
Details of the Upcoming Investor Conference
Pharming’s management team will be actively engaged during the following event in November:
Jefferies London Healthcare Conference 2024
Scheduled for November 19-21, the Jefferies London Healthcare Conference will feature Sijmen de Vries, the Chief Executive Officer of Pharming. He will present on Wednesday, November 20 at 08:00 GMT/09:00 CET. Attendees can look forward to a comprehensive presentation that highlights Pharming's innovative therapies and strategic initiatives.
How to Connect with Pharming
For those interested in more information about the investor conference or wishing to arrange a one-on-one meeting with Pharming’s management, direct inquiries should be made to the Investor Relations team at Pharming.
They can be reached via email. This presents an excellent opportunity for investors to discuss Pharming’s advancements and explore possible collaborations or investments.
About Pharming Group N.V.
Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is recognized as a leader in the biopharmaceutical sector, focusing on transforming the lives of patients suffering from rare and serious diseases. With a commitment to developing a robust portfolio of protein replacement therapies and precision medicines, Pharming continues to make significant strides.
With headquarters located in Leiden, the Netherlands, Pharming operates globally, employing dedicated professionals who serve patients across over 30 markets including segments in North America, Europe, the Middle East, Africa, and Asia-Pacific regions.
Innovations and Developments at Pharming
Pharming is at the forefront of introducing groundbreaking biologics that promise to enhance patient outcomes. Their focus on innovation has led to promising advancements in the biopharmaceutical landscape, particularly as they explore additional therapeutic areas and expand their global reach.
Investors are encouraged to stay informed about Pharming's developments and findings through their official channels, which highlight ongoing projects and future prospects within the industry.
Contact Information
For any further inquiries or public information regarding Pharming, please refer to:
Pharming Group, Leiden, the Netherlands
Michael Levitan, VP Investor Relations & Corporate Communications
T: +1 (908) 705 1696
E: investor@pharming.com
Frequently Asked Questions
What is the purpose of Pharming's participation in the investor conference?
Pharming aims to engage with investors to provide updates on its innovative therapies, corporate strategy, and future growth plans.
When will Pharming's presentation at the Jefferies London Conference occur?
The presentation by Sijmen de Vries, CEO, is scheduled for November 20 at 08:00 GMT/09:00 CET.
How can investors contact Pharming for more information?
Investors can reach out to Pharming's Investor Relations team via email to request more information or schedule meetings.
What types of therapies does Pharming focus on?
Pharming specializes in protein replacement therapies and precision medicines aimed at treating rare and serious diseases.
Where is Pharming headquartered?
Pharming is based in Leiden, the Netherlands, with a global presence across many key markets.
